Applications

1370 – Ocriplasmin for symptomatic vitreomacular adhesion (sVMA) including macular hole

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome Supported

Application details

Reason for application

New MBS item.

Service or technology in this application

Optical coherence tomography (OCT) is part of standard clinical practice for diagnosing a wide range of macular and retinal diseases. It is proposed that OCT be used as a procedure in patients with sVMA including those associated with full thickness macular hole (FTMH) for the purpose of identifying eligibility for treatment with ocriplasmin (on the Pharmaceutical Benefits Scheme); and for assessment of treatment outcome.

Type: Co-dependent technology

Medical condition this application addresses

Vitreomacular interface disorders describe a group of pathologies each with their own distinctive features that distort or blur vision and potentially impair central visual acuity, including vitreomacular adhesion/traction and macular holes.

Application documents

PICO confirmation

Public summary document – November 2014:

Public summary document – March 2016

Public summary document – Consumer friendly

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Meetings to consider this application

  • PASC meeting: 12 December 2013
  • ESC meeting: 8 October 2014
  • MSAC meeting: 
    • 26 November 2014
    • 30 March 2016